Pfizer (PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including the Eliquis, Chantix/Champix, Prevnar, Lipitor and Viagra brands.
Over the past year, Pfizer has been consumed by the development and distribution of its COVID-19 vaccine, but that hasn't been the only source of its success. Its big name drugs, including Eliquis and Xeljanz delivered strong revenue growth, and prescription demand remained solidly on the rise. The company has mostly recovered from COVID recession weaknesses and margins are back to above average levels within the industry.
With financials back in a solid place, investors will find the stock's 3.9% forward-looking yield attractive. Pfizer is building on an 11-year dividend growth streak having last reduced its quarterly shareholder payment during the depths of the financial crisis.
This report for Pfizer is through May 2021.
You can find the full report on Pfizer below, but here are a few of the highlights.
- Pfizer's delivery of its COVID-19 vaccine exceeded its government contractual obligations and is currently at 430 million doses worldwide and counting.
- The company's return on assets and net profit margins are among the best in the industry.
- The current ratio and quick ratio suggest the company is in good financial condition and should not have trouble meeting some of its short-term obligations.
- RSI and MACD are both relatively neutral indicating no particular value in shares at current levels.
- Analysts are relatively neutral on the stock with the consensus price target at around 6% above the current share price.
- Pfizer has a dividend yield of 3.9% and has raised its dividend for 11 consecutive years.